
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
PHARMASEAL International has announced that it will offer the Engility CTMS solution at no cost for COVID-19 Coronavirus clinical trials. The offer is open to biopharmaceutical organizations and academic institutions.
For more information, click






